Skip to main content

Table 1 Clinical features of the 208 matched-pair patients with nasopharyngeal carcinoma

From: Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone

Characteristic NACT+CCRT group CCRT group
(n = 104, %) (n = 104, %)
Age, years
  ≤ 50 86 (82.7) 86 (82.7)
  > 50 18 (17.3) 18 (17.3)
Gender   
 Male 82 (78.8) 82 (78.8)
 Female 22 (21.2) 22 (21.2)
T category a
 T1 7 (6.7) 7 (6.7)
 T2 5 (4.8) 5 (4.8)
 T3 63 (60.6) 63 (60.6)
 T4 29 (27.9) 29 (27.9)
N category a
 N0 13 (12.5) 13 (12.5)
 N1 61 (58.7) 61 (58.7)
 N2 22 (21.2) 22 (21.2)
 N3 8 (7.7) 8 (7.7)
Stage b
 III 68 (65.4) 68 (65.4)
 IVA–IVB 36 (34.6) 36 (34.6)
  1. Abbreviations: CCRT concurrent chemoradiotherapy; NACT neoadjuvant chemotherapy
  2. aAccording to the American Joint Committee on Cancer, 7th edition